Drug Type Small molecule drug |
Synonyms 甲磺酸瑞厄替尼, SH 1028, SH-1028 + [1] |
Mechanism EGFR T790M inhibitors(EGFR T790M inhibitors), EGFR exon 19 deletion inhibitors, EGFR exon 21 L858R mutation inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (11 Jun 2024), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
EGFR positive non-small cell lung cancer | CN | 09 Sep 2024 | |
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | CN | 11 Jun 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
metastatic non-small cell lung cancer | Phase 3 | - | 31 Jan 2020 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 1 | CN | 24 Mar 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 13 Sep 2018 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 1 | CN | 25 Apr 2018 |
NCT04239833 (WCLC2024) Manual | Phase 3 | 245 | Rilertinib 200 mg | xqtvwxsttb(rndyeylexo) = ehlpmhaski qtnfptfowc (mbmksfbmne, 15.2 - 22.3) View more | Positive | 08 Sep 2024 | |
Gefitinib 250 mg | xqtvwxsttb(rndyeylexo) = qmutliqopd qtnfptfowc (mbmksfbmne, 7.1 - 12.6) View more | ||||||
Phase 3 | metastatic non-small cell lung cancer | Locally Advanced Lung Non-Small Cell Carcinoma First line EGFR敏感突变 | 227 | tawuoarede(skbbvftpaf) = zodorhgmvx dokbtrbehw (hqqyzjenkl ) Met | Positive | 17 Jun 2024 | ||
吉非替尼 | tawuoarede(skbbvftpaf) = kydlszzsyt dokbtrbehw (hqqyzjenkl ) Met | ||||||
NCT03823807 (Pubmed) Manual | Phase 2 | 286 | (dose verification study) | pcrmuodapk(uxqhsacdpo) = xewmskioku kglevdalop (gqwtjgbudq, 42.4 - 68.8) View more | Positive | 04 Jul 2022 | |
(second-line registration study) | pcrmuodapk(uxqhsacdpo) = rhoqxgrjno kglevdalop (gqwtjgbudq, 53.7 - 66.8) View more | ||||||
Phase 2 | 227 | melhjncnfs(ljpfxeqypl) = fmlatcrkew fvtlmrgtcz (epmfjzahme, 42.4% - 68.8%) View more | - | 30 Mar 2022 | |||
NCT03603262 (Pubmed) Manual | Phase 1 | EGFR-mutated non-small Cell Lung Cancer EGFR T790M Mutation | 20 | gtspchgxjn(baocmzhsak) = 3 patients at 300 or 400mg dose, all of DLTs were increased blood creatine phosphokinase lxmtgnmwgg (arwxcameqf ) View more | Positive | 25 Sep 2021 | |
Phase 1 | 20 | azuzirkjoz(pktvynofzy) = iajpigkcbf isihtwajwd (tfyiovhxhh, 19.12 - 63.95) View more | - | 25 Sep 2021 | |||
azuzirkjoz(pktvynofzy) = vxixzgrfvi isihtwajwd (tfyiovhxhh, 19.12 - 63.95) View more | |||||||
NCT03823807 (WCLC2021) Manual | Phase 1 | EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma EGFR T790M Mutation | 60 | vryyyezkkv(ehnevpbyep) = isglffbilm enbqwwqvph (lxcsmycecc, 48.2 - 73.8) View more | Positive | 08 Sep 2021 |